Cidara Therapeutics, Inc.
CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio—
52W High$221.42
52W Low$15.22
Cidara Therapeutics, Inc. (CDTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CDTX · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 6, 2025EPS Actual
-$1.43
Est. -$1.34 · -6.7%
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 6, 2025
After Market Close
▼ Miss EPS
CDTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -$1.34 | -$1.43 | -6.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$1.87 | -$1.65 | +11.8% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$5.45 | -$1.66 | +69.5% | — | — | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$5.28 | -$5.38 | -1.9% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$5.22 | -$2.38 | +54.4% | — | $0.00B | — |
| ▲ Q3 FY2024 | Aug 13, 2024 | -$3.94 | -$2.05 | +48.0% | $0.00B | $0.00B | -93.6% |
| ▼ Q2 FY2024 | Apr 22, 2024 | -$0.20 | -$0.80 | -300.0% | $0.01B | $0.01B | +34.3% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -$0.10 | -$0.19 | -90.0% | $0.02B | $0.01B | +52.4% |
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$1.43
EPS Est.
-$1.34
EPS Surpr.
-6.7%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$1.65
EPS Est.
-$1.87
EPS Surpr.
+11.8%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$1.66
EPS Est.
-$5.45
EPS Surpr.
+69.5%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$5.38
EPS Est.
-$5.28
EPS Surpr.
-1.9%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$2.38
EPS Est.
-$5.22
EPS Surpr.
+54.4%
Revenue
—
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
-$2.05
EPS Est.
-$3.94
EPS Surpr.
+48.0%
Revenue
$0.00B
Q2 FY2024
Apr 22, 2024Miss
EPS Actual
-$0.80
EPS Est.
-$0.20
EPS Surpr.
-300.0%
Revenue
$0.01B
Q1 FY2024
Mar 28, 2024Miss
EPS Actual
-$0.19
EPS Est.
-$0.10
EPS Surpr.
-90.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.93 | $-0.93 | $-0.93 | 1 |
| Q3 FY2026 | $-0.96 | $-0.96 | $-0.96 | 1 |
| Q2 FY2026 | $-0.99 | $-0.99 | $-0.99 | 1 |
| Q1 FY2026 | $-1.04 | $-1.04 | $-1.04 | 1 |
| Q4 FY2025 | $-1.68 | $-1.58 | $-1.44 | 3 |
| Q3 FY2025 | $-1.40 | $-1.34 | $-1.19 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 6, 2025 | -6.7% | $97.64 | $98.64 | +1.02% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +11.8% | $61.99 | $61.73 | -0.42% |
| ▲ Q2 FY2025 | May 8, 2025 | +69.5% | $18.98 | $19.15 | +0.90% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -1.9% | $23.50 | $23.61 | +0.47% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +54.4% | $13.26 | $13.11 | -1.13% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +48.0% | $11.73 | $12.15 | +3.58% |
| ▼ Q2 FY2024 | Apr 22, 2024 | -300.0% | $13.62 | $10.28 | -24.52% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -90.0% | $16.84 | $18.40 | +9.26% |
Q4 FY2025+1.02%
Report Date
Nov 6, 2025
EPS Beat/Miss
-6.7%
Price Before
$97.64
Price After
$98.64
Q3 FY2025-0.42%
Report Date
Aug 7, 2025
EPS Beat/Miss
+11.8%
Price Before
$61.99
Price After
$61.73
Q2 FY2025+0.90%
Report Date
May 8, 2025
EPS Beat/Miss
+69.5%
Price Before
$18.98
Price After
$19.15
Q1 FY2025+0.47%
Report Date
Mar 6, 2025
EPS Beat/Miss
-1.9%
Price Before
$23.50
Price After
$23.61
Q4 FY2024-1.13%
Report Date
Nov 7, 2024
EPS Beat/Miss
+54.4%
Price Before
$13.26
Price After
$13.11
Q3 FY2024+3.58%
Report Date
Aug 13, 2024
EPS Beat/Miss
+48.0%
Price Before
$11.73
Price After
$12.15
Q2 FY2024-24.52%
Report Date
Apr 22, 2024
EPS Beat/Miss
-300.0%
Price Before
$13.62
Price After
$10.28
Q1 FY2024+9.26%
Report Date
Mar 28, 2024
EPS Beat/Miss
-90.0%
Price Before
$16.84
Price After
$18.40
Avg Beat Reaction+0.73%
Avg Miss Reaction-3.44%
Beat Rate4 / 8 quarters
Largest Move-24.52% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CDTX ends December
Cidara Therapeutics, Inc. (CDTX) most recently reported earnings on November 6, 2025 for Q4 FY2025, posting EPS of $-1.43 — missing the analyst consensus of $-1.34 by -6.7%. The next CDTX earnings date is expected around September 1, 2026.
Each quarter, investors track CDTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CDTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CDTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CDTX earnings · 5 questionsCidara Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CDTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CDTX historically reports after market close (AMC).
CDTX earnings datewhen is CDTX earningsCDTX next earnings datewhen does CDTX report earningsCDTX earnings calendar
▸ Source: FMP · Cidara Therapeutics, Inc. SEC filings · US GAAP · Cidara Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026